Indofarma Tbk (INAF) - Total Assets

Latest as of September 2025: Rp581.56 Billion IDR ≈ $34.08 Million USD

Based on the latest financial reports, Indofarma Tbk (INAF) holds total assets worth Rp581.56 Billion IDR (≈ $34.08 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Indofarma Tbk - Total Assets Trend (2000–2024)

This chart illustrates how Indofarma Tbk's total assets have evolved over time, based on quarterly financial data. Also see INAF market cap overview for the company's overall valuation and market capitalisation.

Indofarma Tbk - Asset Composition Analysis

Current Asset Composition (December 2024)

Indofarma Tbk's total assets of Rp581.56 Billion consist of 21.7% current assets and 78.3% non-current assets. Review how much debt does Indofarma Tbk carry to assess the company's total debt and financial obligations.

Asset Category Amount (IDR) % of Total Assets
Cash & Equivalents Rp0.00 1.6%
Accounts Receivable Rp46.92 Billion 7.6%
Inventory Rp33.33 Billion 5.4%
Property, Plant & Equipment Rp383.13 Billion 62.0%
Intangible Assets Rp2.88 Billion 0.5%
Goodwill Rp0.00 0.0%

Asset Composition Trend (2000–2024)

This chart illustrates how Indofarma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Indofarma Tbk for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Indofarma Tbk's current assets represent 21.7% of total assets in 2024, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 9.6% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
  • Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.

Indofarma Tbk Competitors by Total Assets

Key competitors of Indofarma Tbk based on total assets are shown below.

Company Country Total Assets
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Beijing Tongrentang Co Ltd
SHG:600085
China CN¥31.82 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Neuland Laboratories Limited
NSE:NEULANDLAB
India Rs29.30 Billion
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
China CN¥17.01 Billion

Indofarma Tbk - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.13 0.15 1.36
Quick Ratio 0.10 0.07 1.18
Cash Ratio 0.00 0.00 0.00
Working Capital Rp-1.09 Trillion Rp-1.21 Trillion Rp297.98 Billion

Indofarma Tbk - Advanced Valuation Insights

This section examines the relationship between Indofarma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.53
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -18.6%
Total Assets Rp618.16 Billion
Market Capitalization $22.88 Million USD

Valuation Analysis

Below Book Valuation: The market values Indofarma Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Indofarma Tbk's assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Indofarma Tbk (2000–2024)

The table below shows the annual total assets of Indofarma Tbk from 2000 to 2024.

Year Total Assets Change
2024-12-31 Rp618.16 Billion
≈ $36.22 Million
-18.64%
2023-12-31 Rp759.83 Billion
≈ $44.52 Million
-50.47%
2022-12-31 Rp1.53 Trillion
≈ $89.89 Million
-23.75%
2021-12-31 Rp2.01 Trillion
≈ $117.89 Million
+17.42%
2020-12-31 Rp1.71 Trillion
≈ $100.39 Million
+23.80%
2019-12-31 Rp1.38 Trillion
≈ $81.09 Million
-4.05%
2018-12-31 Rp1.44 Trillion
≈ $84.52 Million
-5.72%
2017-12-31 Rp1.53 Trillion
≈ $89.64 Million
+10.73%
2016-12-31 Rp1.38 Trillion
≈ $80.96 Million
-9.92%
2015-12-31 Rp1.53 Trillion
≈ $89.87 Million
+22.86%
2014-12-31 Rp1.25 Trillion
≈ $73.15 Million
-3.57%
2013-12-31 Rp1.29 Trillion
≈ $75.85 Million
+8.91%
2012-12-31 Rp1.19 Trillion
≈ $69.65 Million
+6.61%
2011-12-31 Rp1.11 Trillion
≈ $65.33 Million
+51.90%
2010-12-31 Rp733.96 Billion
≈ $43.01 Million
+0.81%
2009-12-31 Rp728.03 Billion
≈ $42.66 Million
-24.62%
2008-12-31 Rp965.81 Billion
≈ $56.59 Million
-4.32%
2007-12-31 Rp1.01 Trillion
≈ $59.15 Million
+46.95%
2006-12-31 Rp686.94 Billion
≈ $40.25 Million
+32.40%
2005-12-31 Rp518.82 Billion
≈ $30.40 Million
-0.97%
2004-12-31 Rp523.92 Billion
≈ $30.70 Million
-17.62%
2003-12-31 Rp635.96 Billion
≈ $37.26 Million
-21.49%
2002-12-31 Rp810.03 Billion
≈ $47.46 Million
-0.20%
2001-12-31 Rp811.62 Billion
≈ $47.56 Million
+50.81%
2000-12-31 Rp538.17 Billion
≈ $31.53 Million
--

About Indofarma Tbk

JK:INAF Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$22.88 Million
Rp390.51 Billion IDR
Market Cap Rank
#24770 Global
#528 in Indonesia
Share Price
Rp126.00
Change (1 day)
+0.00%
52-Week Range
Rp126.00 - Rp126.00
All Time High
Rp6975.00
About

PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more